Related Experiment Video

Updated: May 22, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Antiangiogenic approaches for the treatment of advanced synovial sarcomas

Khanh Do1, James H Doroshow, Shivaani Kummar

  • 1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

Current Opinion in Oncology
|May 11, 2012
PubMed
Abstract

Insights

Advanced synovial sarcoma treatment shows promise with anti-angiogenic therapies targeting vascular endothelial growth factor receptor (VEGFR). These targeted treatments, including pazopanib, offer improved outcomes for this challenging cancer.

Area of Science:

  • Oncology
  • Medical Research
  • Cancer Therapy

Background:

  • Synovial sarcomas are soft tissue sarcomas with poor prognosis in advanced stages.
  • Current treatments have limited impact on survival for advanced refractory disease.
  • Sarcomas exhibit vascularity, making antiangiogenic approaches a focus for targeted therapy.

Purpose of the Study:

  • To review the efficacy of antiangiogenic therapies in advanced synovial sarcoma.
  • To explore the potential of targeting vascular endothelial growth factor receptor (VEGFR) in sarcoma management.
  • To assess the impact of targeted therapies on patient outcomes.

Main Methods:

  • Review of recent studies on oral VEGFR inhibitors (sunitinib, sorafenib, cediranib, pazopanib).
  • Analysis of clinical trial data for advanced synovial sarcoma patients.
  • Evaluation of disease stabilization and progression-free survival rates.

Main Results:

  • Oral VEGFR inhibitors like sunitinib, sorafenib, and cediranib demonstrated disease stabilization.
  • Pazopanib showed no evidence of disease progression at 12 weeks in 49% of advanced synovial sarcoma patients.
  • Anti-VEGF therapies have shown preliminary activity in synovial sarcomas.

Conclusions:

  • Anti-VEGF therapies offer improved outcomes compared to chemotherapy in advanced soft tissue sarcomas.
  • Targeted combinations of anti-VEGF agents with other pathway inhibitors hold potential for better treatment results.
  • Further research into combination therapies is warranted for this difficult-to-treat disease.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...